IntegraGen Partners with CRUK to Validate miRNA Marker for Colorectal Cancer Drug Response | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics firm IntegraGen said today that it is collaborating with Cancer Research UK to validate a microRNA as a biomarker for the prediction of progression-free survival in patients with metastatic colorectal cancer who have received anti-EGFR therapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.